Published in Cancer Weekly, January 4th, 2005
"The DNA-damaging agent bleomycin arrests the cell cycle at the G2 phase of Jurkat cells defective in the G1 checkpoint, and microtubule-acting colchicine arrests it at the M phase," scientists in Japan explained.
"Boromycin itself, an actinomycete metabolite, showed no effect on the cell cycle status of Jurkat cells at least up to 340 nM," in a study conducted by M. Arai and coauthors at Kitasato University. "However, the compound (3.4-340 nM) was found to abrogate bleomycin-induced G2 arrest even at 3.4...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.